Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258780 | 0.97 | NAAA (0.66) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL31069913 | 0.97 | NAAA (0.66) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL7568980 | 0.97 | NAAA (0.66) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL28448079 | 0.95 | NAAA (0.59) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL3473161 | 0.91 | NAAA (0.56) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL31302650 | 0.91 | NAAA (0.59) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL1980866 | 0.90 | NAAA (0.71) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL17675339 | 0.90 | NAAA (0.78) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL19690548 | 0.89 | NAAA (0.52) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL3472508 | 0.89 | NAAA (0.58) | NAAACYP2C19HTTCYP19A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | claimed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | claimed |
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2025-05-15 | — | — | US | disclosed |
| US-12173021-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024225072-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PRODUCTION METHOD FOR CURED RELIEF PATTERN, AND CURED FILM | 旭化成株式会社 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024210063-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING CURED RELIEF PATTERN, CURED FILM, AND SEMICONDUCTOR DEVICE | 旭化成株式会社 | 2024-10-10 | — | — | WO | disclosed |
| CN-108473752-B | Resin composition and use thereof | 日本瑞翁株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| CN-117445376-A | Method for manufacturing polarizing plate | 日本瑞翁株式会社 | 2024-01-26 | — | — | CN | disclosed |
| US-11634443-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| CN-114716591-A | Catalyst component for propylene polymerization, preparation method and application thereof | 任丘市利和科技发展有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-1268450-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| CN-1386118-A | Lactams substituted by cyclic succinates as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB CO (US) | 2002-12-18 | — | — | CN | disclosed |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | disclosed |
| WO-2001092235-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-0240723-B1 | UV-LIGHT STABILIZER COMPOSITION COMPRISING CYCLIC ALIPHATIC EPOXY, UV SCREENER, AND POLYALKYLDIPIPERIDINE (HALS) COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5026751-A | For a polyphenylene ether, 2-hydroxybenzophenone | GENERAL ELECTRIC COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| US-4843116-A | SHAPED PLASTICS | GENERAL ELECTRIC COMPANY (US) | 1989-06-27 | — | — | US | disclosed |
| EP-0240723-A2 | UV-light stabilizer composition comprising cyclic aliphatic epoxy, UV screener, and polyalkyldipiperidine (HALS) compounds | GENERAL ELECTRIC COMPANY (US) | 1987-10-14 | — | — | EP | disclosed |
| US-4005055-A | Anaerobic aminimide curing compositions | SKEIST LABORATORIES, INCORPORATED (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | NAAA 178/4885CYP2C19 44/4885HTT 2504/4885 |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | APP, BACE1, APH1A | NAAA 264/4885CYP2C19 1406/4885HTT 770/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | NAAA 119/4885CYP2C19 1438/4885HTT 732/4885 |
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | NAAA 178/4885CYP2C19 44/4885HTT 2504/4885 |
| US-12173021-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | NAAA 178/4885CYP2C19 44/4885HTT 2504/4885 |
| US-11634443-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | NAAA 178/4885CYP2C19 44/4885HTT 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.